


FEBRUARY 20, 2026

BB Biotech

FY 2025 investor presentation



Caution regarding forward-looking statements





This marketing document relates to BB Biotech AG (hereinafter the "Company"). In Switzerland, the Company is structured as a holding company with fixed capital (SICAF, cf. Art. 110 ff. of the Swiss Collective Investment Schemes Act, "CISA"), but it is not subject to the CISA due to its listing on the SIX Swiss Exchange and the German Stock Exchange (Art. 2 para. 3 and Art. 110 para. 1c CISA); instead, the Company is subject to the supervision of the respective stock exchange authorities. This marketing document is issued by Bellevue Asset Management AG, which is an authorized asset manager subject to the supervision of the Swiss Financial Market Supervisory Authority (FINMA) and which acts as the Investment Manager of the Company.

This communication is issued in the UK by Bellevue Asset Management (UK) Ltd, which is authorized and regulated by the Financial Conduct Authority (FRN: 825152). Consequently, this communication is only made available to professional clients and eligible counterparties as defined by the FCA. The rules made under the Financial Services and Markets Act 2000 for the protection of retail clients may not apply. The Financial Services Compensation Scheme is unlikely to be available.

The prospectus, statutes, the annual and quarterly reports, share price information and other data about the Company can be obtained free of charge in English and German from the Company, BB Biotech AG, Schwertstrasse 6, CH-8200 Schaffhausen, from the Investment Manager of the Company, Bellevue Asset Management AG, Theaterstrasse 12, CH-8001 Zürich, or online at www.bbbiotech.com.

This document is neither directed to, nor intended for distribution to or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. In particular, it is not intended for distribution to any US person within the meaning of Regulation S of the US Securities Act of 1933, as amended. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to buy any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. This information does not take into account the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient and in particular tax treatment depends on individual circumstances and may be subject to change. This document is not to be relied upon in substitution for the exercise of independent judgment. Before making an investment decision, investors are recommended to ascertain if this investment is suitable for them in the light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. The details and opinions contained in this document are not to be considered as a recommendation or as investment advice. Every investment involves risk, especially with regard to fluctuations in value and return, and investors' capital may be at risk. If the currency of a financial product is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. Past performance is not an indicator of the current or future performance. Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or the investment universe of the Company. The performance of a benchmark is not an indicator of the Company's past or future performance. Financial transactions should only be undertaken after having carefully studied the current valid prospectus and they are only valid on the basis of the latest version of the prospectus and available annual and quarterly reports. Please take note of the risk factors.

Table of contents

- 1  Performance and value realisation
- 2  Portfolio structure and risk framework
- 3  Growth drivers and catalysts 2026
- 4  Long-term shareholder value

FY 2025 at a glance

Net profit

FY 2025 CHF 578 mn


FY 2024 CHF 76 mn

Q4 2025 CHF 472 mn

Q4 2024 CHF 60 mn

BB Biotech combines disciplined capital allocation, structural M&A exposure and a catalyst-dense portfolio to generate long-term value across cycles.


in CHF / %



	in CHF	in EUR	in USD
BB Biotech Share	+34.2%	+37.0%	+53.7%
Net Asset Value (NAV)	+26.5%	+27.8%	+44.8%
Nasdaq Biotech Index (NBI)	+16.6%	+17.7%	+33.4%

Broad-based outperformance driven by high-conviction positioning

Top 10 performing portfolio holdings in 2025




- Top contributors driven by clinical and regulatory milestones
- Multiple >50% performers across therapeutic areas
- Mix of core and newly initiated positions

FY 2025: disciplined positioning across the biotech lifecycle

The S-curve as a structural tool for sizing, risk control and timing

- Conviction-led portfolio construction
- Clear return hurdle at entry
- Dynamic sizing across development stages
- Disciplined exits and capital redeployment
- Risk-aware scaling of exposure



* BioMarin announced on December 19, 2025, its acquisition of Amicus Therapeutics.

** Novartis announced on October 26, 2025, its agreement to acquire Avidity Biosciences.

Source: Bellevue Asset Management AG

Disciplined capital allocation powered by our proprietary platform




- Structured scenario analysis
Probability-weighted valuation across base, upside and downside cases
- Integrated risk assessment
Position sizing and capital allocation aligned with maturity and liquidity
- Continuous portfolio monitoring
Reassessment as clinical data, catalysts and market conditions evolve

Mid-cap concentration at the steepest part of the value curve

Portfolio positioning versus the benchmark

- Overweight mid-cap innovators (5–30bn)
- Complemented by selective large-cap exposure
- Reduced exposure to early-stage small caps



Biotech sector backdrop: selective recovery within structural transformation



- Valuation reset largely behind us
financing conditions stabilized,
sentiment improved, focus shifted
back to fundamentals
- Structural drivers intact
patent cliff and external innovation
needs support sustained strategic
demand
- Selective opportunity set
differentiation, clinical maturity and
execution increasingly determine
value creation



Structural M&A backdrop and BB Biotech positioning

Industry context

- Patent cliff drives external innovation
- Balance sheets enable strategic acquisitions

BB Biotech positioning

- Portfolio aligned with Big Pharma priorities
- 5 acquisitions in 2025 validate positioning
- Disciplined selection ahead of strategic demand

M&A companies in BB Biotech's portfolio



Intra-Cellular Therapies



Blueprint Medicines



Akero



Avidity



Amicus

Pipeline depth reflects clinical maturity and differentiation

2026 driven by catalyst-rich execution

- Increasing exposure to Phase III and registrational-stage assets
- Concentrated in immunology, oncology and rare diseases
- Focus on validated mechanisms and scalable platforms
- Clinical progress translating into commercial and M&A relevance
- Portfolio positioned for selective value realization

Selected key milestones 2026

- Revolution Medicines – Phase III data for daraxonrasib in pancreatic cancer
- Argenx – Multiple Phase III readouts across the Vyvgart franchise and MMN data for empa*
- Viridian Therapeutics – Phase III data for elegrobar in thyroid eye disease and potential approval/launch of veligrotug in H2 2026
- Ionis Pharmaceuticals – Commercial launch of Tryngolza in sHTG
- Vertex Pharmaceuticals – Renal focus including povetacicept clinical progress

*empasiprubart

Long-term investing that translates into tangible shareholder returns



- Proposed dividend of CHF 2.25 per share for FY 2025.
- New share buyback program of up to 10% over three years.
- Active capital management to address discount
- Confirmed ESG integration through SPI ESG Index inclusion.



- Disciplined execution.
- Structural tailwinds.
- Catalyst-rich portfolio.
- Positioned for sustainable long-term value creation.

Contact

Bellevue Asset Management AG
Theaterstrasse 12
CH-8001 Zürich

Tel. +41 44 267 67 00
E-Mail: info@bellevue.ch
www.bbbiotech.com

Investor Relations:
ir@bbbiotech.com

Rachael Burri
Head Investor Relations, rbi@bellevue.ch

